Drug Safety Fears May Limit Reimporting and Shape R&D

Concerns about risky medicines may reduce pressure to expand drug imports while boosting demand for more comparative analyses of therapies.

Related Content:

Quality SystemsRegulatory Oversight and CompliancePharmaceutical Technology-02-02-2005

A CDMO’s Role in API Quality

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

GSK, Spero Therapeutics Oral UTI Treatment Trial Stopped Early for Efficacy